Our founders’ insights and achievements
08 Jan 2026: AbolerIS Pharma Announces First Patient Dosed in Part II of Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis
08 Jan 2026: NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s
27 Oct 2025: Adaptam Therapeutics raises €3 million to pioneer cancer immunotherapies against immunosuppressive myeloid cells
08 Sep 2025: NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
23 Jul 2025: Leriglitazone Marketing Authorization Application submitted for treatment of cerebral adrenoleukodystrophy has been validated by European Medicines Agency
17 Jul 2025: Minoryx receives a EUR 26.9m grant within the framework of the European IPCEI Med4Cure project for the continued development of leriglitazone in lethal orphan CNS diseases
07 May 2025: AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis
29 Oct 2024: MedLumics New CEO and Board Member Announces 10 Patients Treated in First in Man (FIM) Clinical Trial With the Real-Time Visually Guided AblaView PFA System
15 Oct 2024: Tolerance Bio, Inc. launches with $17.2 million in seed financing to advance thymus-based therapies for immune-mediated diseases